Pds Biotechnology Corp (PDSB) Stock Price, Quote & News

Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies. The company's lead product candidate is Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T c...

Industry: Biotechnology

Sector: Healthcare

Phone: 800 208 3343

Website: www.pdsbiotech.com

Address:

303A College Road East, Princeton, United States

ThatNurseDude Jan. 15 at 2:40 PM

$PDSB doesn’t make sense to be running ads on cnbc if there’s a partnership lined up, right?

1 · Reply

vijaykamat14 Jan. 14 at 8:20 PM

$PDSB

0 · Reply

CrispDry Jan. 14 at 7:46 PM

$PDSB rofl. They are now spending money running 15 second cnbc commercials? Sorry guys. This company is dead. They are simply begging retail to save them.

3 · Reply

Ontherag Jan. 14 at 5:45 PM

$PDSB 4500 open interest on 2/20 2.5 calls

0 · Reply

Ontherag Jan. 14 at 4:49 PM

$PDSB

0 · Reply

Mr_Charlie Jan. 14 at 3:49 PM

$PDSB this shite MREO is now over 200% up since drop and here we are stuck under 1 dolar without even signs that we will go up 50%. Such a misery stock.

1 · Reply

dvice2 Jan. 13 at 6:00 PM

$PDSB looks like data for this trial (NCT04491955) with PDS01ADC was published by Oxford University a few days ago. bit of nothing burger although the 1 CR with 29+ months durability came from combo using PDS01ADC. https://academic.oup.com/oncolo/advance-article/doi/10.1093/oncolo/oyag008/8419904?login=false

1 · Reply

i81b4u Jan. 13 at 2:48 AM

$PDSB Question does a 1.00 count for the market closes at 4:pm or 8:pm?

3 · Reply

Aboutaam Jan. 12 at 8:51 PM

$PDSB see you at 1.35 good pullback today for some relief

0 · Reply

MarketGovernor Jan. 12 at 7:35 PM

$PDSB why falling today?

2 · Reply

PDS Biotech Announces FDA Alignment on use of Progression Free Survival (PFS) as Primary Endpoint

Dec 9, 2025, 8:00 AM EST - 5 weeks ago

PDS Biotech Announces New Composition of Matter Patent for PDS0101 in Japan

Dec 2, 2025, 8:30 AM EST - 6 weeks ago

PDS Biotech Announces Scheduling of Type C Meeting with U.S. Food and Drug Administration (“FDA”)

Nov 13, 2025, 10:11 AM EST - 2 months ago

PDS Biotechnology Corporation (PDSB) Q3 2025 Earnings Call Transcript

Nov 13, 2025, 7:30 AM EST - 2 months ago

PDS Biotech Reports Third Quarter 2025 Financial Results and Provides Clinical Programs Update

Nov 11, 2025, 3:31 PM EST - 2 months ago

PDS Biotechnology Announces up to $11.1 Million Registered Direct Offering

Nov 10, 2025, 8:30 AM EST - 2 months ago

PDS Biotechnology Announces Translational Data Showing Strong Immunological and Clinical Activity of PDS0101 and PDS01ADC Presented at SITC 2025

Nov 6, 2025, 8:00 AM EST - 2 months ago

PDS Biotech Announces Conference Call and Webcast for Third Quarter 2025 Financial Results

Oct 30, 2025, 8:00 AM EDT - 2 months ago

New Clinical and Translational Data on PDS Biotechnology's Novel Investigational Cancer Therapies PDS0101 and PDS01ADC to be Presented at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Oct 29, 2025, 8:37 AM EDT - 2 months ago

PDS Biotech to Seek Expedited Approval Pathway for PDS0101 in HPV16-Positive Head and Neck Cancer

Sep 18, 2025, 8:45 AM EDT - 4 months ago

PDS Biotech Sets Significant Benchmark in Head and Neck Cancer by Achieving Extended Survival in Low PD-L1 Expression (CPS 1–19) Cohort in VERSATILE-002 Trial, Potentially Eliminating Need for Chemotherapy in the Population

Sep 2, 2025, 8:00 AM EDT - 4 months ago

PDS Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Aug 25, 2025, 8:30 AM EDT - 5 months ago

PDS Biotech Announces Final Topline Survival Data from VERSATILE-002 Phase 2 Trial in Head and Neck Cancer

Aug 13, 2025, 10:08 AM EDT - 5 months ago

PDS Biotechnology Corporation (PDSB) Q2 2025 Earnings Call Transcript

Aug 13, 2025, 7:00 AM EDT - 5 months ago

PDS Biotech Reports Second Quarter 2025 Financial Results and Provides Clinical Programs Update

Aug 6, 2025, 8:00 AM EDT - 5 months ago

PDS Biotech Announces Conference Call and Webcast for Second Quarter 2025 Financial Results

Jul 10, 2025, 8:00 AM EDT - 6 months ago

PDS Biotech Announces Colorectal Cancer Cohort of Phase 2 Clinical Trial with PDS01ADC Met Criteria for Expansion to Stage 2 Following Positive Stage 1 Results

Jun 9, 2025, 8:00 AM EDT - 7 months ago

PDS Biotech to Host Key Opinion Leader Event to Discuss Versamune® HPV for the Treatment of HPV16+ HNSCC

Jun 2, 2025, 8:00 AM EDT - 8 months ago

PDS Biotech Unveils Updated Positive Data From VERSATILE-002 Trial and Additional Trials Evaluating Versamune® HPV to Treat Head and Neck Cancers at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

May 22, 2025, 5:26 PM EDT - 8 months ago

PDS Biotech Announces Positive Extended Follow-Up Data for VERSATILE-002 and Additional Trials Evaluating Versamune® HPV to be Presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

May 20, 2025, 8:00 AM EDT - 8 months ago

PDS Biotech to Participate at the A.G.P. Virtual Annual Healthcare Company Showcase

May 14, 2025, 12:57 PM EDT - 8 months ago

PDS Biotechnology Corporation (PDSB) Q1 2025 Earnings Call Transcript

May 14, 2025, 7:30 AM EDT - 8 months ago

PDS Biotech Reports First Quarter 2025 Financial Results and Provides Clinical Programs and Corporate Update

May 9, 2025, 4:05 PM EDT - 8 months ago

PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 8, 2025, 8:00 AM EDT - 9 months ago

PDS Biotech Announces Additional Details on Two Preclinical Universal Influenza Presentations at IMMUNOLOGY2025™ Annual Meeting

May 7, 2025, 8:00 AM EDT - 9 months ago

PDS Biotech Announces Conference Call and Webcast for First Quarter 2025 Financial Results

Apr 23, 2025, 10:16 AM EDT - 9 months ago

PDS Biotech Announces Multiple Abstracts Selected for Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 16, 2025, 8:00 AM EDT - 9 months ago

PDS Biotech Announces Preclinical Influenza Data to be Presented in Symposium at IMMUNOLOGY2025™ Annual Meeting

Apr 8, 2025, 8:00 AM EDT - 10 months ago

PDS Biotech Announces PDS01ADC Clinical Data to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025

Mar 27, 2025, 10:35 AM EDT - 10 months ago

PDS Biotechnology Corporation (PDSB) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 7:30 AM EDT - 10 months ago

PDS Biotech Reports Full Year 2024 Financial Results and Provides Clinical Programs Update

Mar 25, 2025, 8:00 AM EDT - 10 months ago

PDS Biotech Leadership to Present at 2025 CAGLA NeauxCancer Conference

Mar 18, 2025, 8:00 AM EDT - 10 months ago

PDS Biotech Announces Conference Call and Webcast for Full Year 2024 Financial Results

Mar 13, 2025, 8:00 AM EDT - 11 months ago

PDS Biotech Announces FDA Clearance of IND Application for Combination of Versamune® MUC1 and PDS01ADC to Treat Metastatic Colorectal Cancer

Mar 11, 2025, 8:00 AM EDT - 11 months ago

PDS Biotech Leadership to Participate in March Conferences

Mar 7, 2025, 8:45 AM EST - 11 months ago

PDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck Cancer

Feb 27, 2025, 8:00 AM EST - 11 months ago

PDS Biotech Announces up to $22 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Feb 26, 2025, 8:00 AM EST - 11 months ago

PDS Biotech Announces Positive Clinical Data Demonstrating Compelling Survival and Clinical Responses in Recurrent/Metastatic HPV-Associated Cancers Published in JAMA Oncology

Feb 24, 2025, 8:00 AM EST - 11 months ago

PDS Biotech Announces Circulating Tumor DNA Results for Versamune® HPV in IMMUNOCERV Trial Published in Clinical Cancer Research

Feb 20, 2025, 8:00 AM EST - 11 months ago

PDS Biotech to Participate at B. Riley Securities Precision Oncology & Radiopharma Conference 2025

Dec 3, 2024, 8:00 AM EST - 1 year ago

PDS Biotech to Host Key Opinion Leader Event on December 17 at 12 p.m. ET

Nov 14, 2024, 11:18 AM EST - 1 year ago

PDS Biotechnology Corporation (PDSB) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 8:00 AM EST - 1 year ago

PDS Biotech to Announce Third Quarter Financial Results on November 14, 2024 at 8:30 a.m. Eastern Time

Oct 2, 2024, 8:00 AM EDT - 1 year ago

PDS Biotech Announces 36-Month Overall Survival Rate of 84.4% in Locally Advanced Cervical Cancer Patients Treated with Versamune® HPV and Chemoradiation

Sep 23, 2024, 10:39 AM EDT - 1 year ago

PDS Biotechnology: Continuing The Holding Pattern

Sep 9, 2024, 8:00 AM EDT - 1 year ago

PDS Biotech to Present Updated VERSATILE-002 Data at ESMO Congress 2024

Sep 3, 2024, 8:00 AM EDT - 1 year ago

PDS Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference

Aug 7, 2024, 8:00 AM EDT - 1 year ago

PDS Biotech to Announce Second Quarter Financial Results on August 13, 2024

Aug 2, 2024, 9:12 AM EDT - 1 year ago

PDS Biotechnology Corporation (PDSB) Clinical Program Update Conference Call (Transcript)

Aug 1, 2024, 7:45 AM EDT - 1 year ago

PDS Biotech Aligns with FDA on Phase 3 Trial in HPV16-Positive First-Line Recurrent or Metastatic Head and Neck Cancer

ThatNurseDude Jan. 15 at 2:40 PM

$PDSB doesn’t make sense to be running ads on cnbc if there’s a partnership lined up, right?

1 · Reply

vijaykamat14 Jan. 14 at 8:20 PM

$PDSB

0 · Reply

CrispDry Jan. 14 at 7:46 PM

$PDSB rofl. They are now spending money running 15 second cnbc commercials? Sorry guys. This company is dead. They are simply begging retail to save them.

3 · Reply

Ontherag Jan. 14 at 5:45 PM

$PDSB 4500 open interest on 2/20 2.5 calls

0 · Reply

Ontherag Jan. 14 at 4:49 PM

$PDSB

0 · Reply

Mr_Charlie Jan. 14 at 3:49 PM

$PDSB this shite MREO is now over 200% up since drop and here we are stuck under 1 dolar without even signs that we will go up 50%. Such a misery stock.

1 · Reply

dvice2 Jan. 13 at 6:00 PM

1 · Reply

i81b4u Jan. 13 at 2:48 AM

$PDSB Question does a 1.00 count for the market closes at 4:pm or 8:pm?

3 · Reply

Aboutaam Jan. 12 at 8:51 PM

$PDSB see you at 1.35 good pullback today for some relief

0 · Reply

MarketGovernor Jan. 12 at 7:35 PM

$PDSB why falling today?

2 · Reply

rwol9999 Jan. 12 at 5:56 PM

$PDSB come on .76 cents again I love it...... Bunch of folks jumped on the news the other day hoping for a big push up now there selling off because they did not get a 20 % pop buy high sell low. I will buy more and wait....

1 · Reply

Ontherag Jan. 12 at 5:29 PM

$PDSB Good volume today…MM owns probably 70% of shares at this point. Frank knows he’s got one shot at a raise or partnership. Something big will happen soon (for better or worse). I’m glad because this has been wasting too much mental energy….not worth it. GL.

1 · Reply

alphabetsop Jan. 12 at 5:15 PM

$PDSB I think one of the X posters has it right. Management is abysmal and the price action speaks directly to that. Does anyone know why the company seemingly refuses to make any changes. We are getting delisted and potential reverse split but they don't seem to give a hoot. I get loyalty but this is beyond comprehension. What does he have on the company?

1 · Reply

DragonOfBosnia Jan. 12 at 5:08 PM

$PDSB pembrolizumab (keytruda) and HPV16 E6 peptides can hopefully help a lot of people, achieve remission. I am big on peptide medicine, have used some myself in the past BPC 157+TB for healing. Semegludite that helps with weight loss also a peptide. Proteins are the workhorses in our bodies. Buy while its cheap...

0 · Reply

Mr_Charlie Jan. 12 at 3:44 PM

$PDSB sell sell sell, unload this shite.

1 · Reply

Mr_Charlie Jan. 12 at 3:35 PM

$PDSB write it there. This is going to end by being sold at 1 dolar, if they can find a buyer!! Not even FDA news can lift the share price. Next will be deslisting letter from Nasdaq. What the hell is this management doing? I am guessing nothing.

0 · Reply

DanishViking92 Jan. 12 at 3:22 PM

$PDSB back to $0.70s before the phase 3 results by Jan 31?

0 · Reply

Mr_Charlie Jan. 12 at 2:20 PM

$PDSB no partner, no confidance of the market in the company. It is easy. Back under a dolar.

1 · Reply

rational1 Jan. 12 at 1:41 PM

$PDSB

0 · Reply

Waffles69 Jan. 10 at 9:23 PM

$PDSB hmmmm probably gonna load up some shares here

2 · Reply

Jack_Nicholson_Truth Jan. 10 at 9:00 PM

$CHRS strange to write the same POSTS here and $PDSB... Super sketchy!!

1 · Reply

Test2025 Jan. 10 at 3:36 PM

$PDSB a lot more bots on X pumping pdsb, whatever can push up the share price pls do it

0 · Reply

Market Cap	47.03M
Revenue (ttm)	0.00
Net Income (ttm)	-37.61M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	1.26

Volume	1,061,500
Avg Vol	807,040
Day's Range	N/A - N/A
Shares Out	48.98M
Stochastic %K	57%
Beta	1.12
Analysts	Strong Sell
Price Target	$7.50